SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-307296
Filing Date
2022-12-16
Accepted
2022-12-16 16:02:27
Documents
16
Period of Report
2022-12-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d438667d8k.htm   iXBRL 8-K 37743
2 EX-10.1 d438667dex101.htm EX-10.1 58980
3 EX-10.2 d438667dex102.htm EX-10.2 30496
4 EX-99.1 d438667dex991.htm EX-99.1 9637
8 GRAPHIC g438667g1215080035490.jpg GRAPHIC 2778
  Complete submission text file 0001193125-22-307296.txt   299393

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA lyel-20221214.xsd EX-101.SCH 2833
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20221214_lab.xml EX-101.LAB 17979
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20221214_pre.xml EX-101.PRE 11247
10 EXTRACTED XBRL INSTANCE DOCUMENT d438667d8k_htm.xml XML 3352
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 221467886
SIC: 2834 Pharmaceutical Preparations